Corbus Pharmaceuticals Holdings, Inc. — Income Charts
1 years of history · ending 2024-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Operating Expenses
Income Breakdown
Revenue
—
R&D
$32M
D&A
$588K
Operating Income
$-49M
EBITDA
$-48M
Interest Expense
$2M
Interest Income
—
Tax Provision
$0
Net Income
$-40M
Operating Margin
—
Net Margin
—
Deferred Tax Assets
$0
DTA Valuation Allowance
$106M
Tax Credit Carryforwards
$11M
NOL Carryforwards
$63M
ETR (Continuing Operations)
0.0%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
2.3%
ETR Foreign Differential (pp)
0.0%
Operating Lease Cost
$1M
Revenue YoY Variation
—
Income YoY Variation
-8.1%